Key points are not available for this paper at this time.
The SMILe-ICM appears to offer survival and rehospitalization benefits, particularly for vulnerable groups, e.g., patients living alone. Larger, adequately powered studies are needed to validate these findings.
Leppla et al. (Tue,) studied this question.